A Simple Key For ABBV-744 BRD4 inhibition in cancer cell lines Unveiled
In Section C, contributors will obtain ABBV-744 and oral navitoclax. In Phase D, participants will acquire ABBV-744 and ruxolitinib. Individuals will get treatment right until disorder progression or the individuals are unable to tolerate the study drugs.and afterwards market H3K27Ac at this area. Chromatin hyperacetylation could increase the acces